Literature DB >> 29550953

PI-RADS v2 and ADC values: is there room for improvement?

Eric J Jordan1, Charles Fiske2, Ronald Zagoria1, Antonio C Westphalen3,4.   

Abstract

PURPOSE: To determine the diagnostic accuracy of ADC values in combination with PI-RADS v2 for the diagnosis of clinically significant prostate cancer (CS-PCa) compared to PI-RADS v2 alone.
MATERIALS AND METHODS: This retrospective study included 155 men whom underwent 3-Tesla prostate MRI and subsequent MR/US fusion biopsies at a single non-academic center from 11/2014 to 3/2016. All scans were performed with a surface coil and included T2, diffusion-weighted, and dynamic contrast-enhanced sequences. Suspicious findings were classified using Prostate Imaging Reporting and Data System (PI-RADS) v2 and targeted using MR/US fusion biopsies. Mixed-effect logistic regression analyses were used to determine the ability of PIRADS v2 alone and combined with ADC values to predict CS-PCa. As ADC categories are more practical in clinical situations than numeric values, an additional model with ADC categories of ≤ 800 and > 800 was performed.
RESULTS: A total of 243 suspicious lesions were included, 69 of which were CS-PCa, 34 were Gleason score 3+3 PCa, and 140 were negative. The overall PIRADS v2 score, ADC values, and ADC categories are independent statistically significant predictors of CS-PCa (p < 0.001). However, the area under the ROC of PIRADS v2 alone and PIRADS v2 with ADC categories are significantly different in both peripheral and transition zone lesions (p = 0.026 and p = 0.03, respectively) Further analysis of the ROC curves also shows that the main benefit of utilizing ADC values or categories is better discrimination of PI-RADS v2 4 lesions.
CONCLUSION: ADC values and categories help to diagnose CS-PCa when lesions are assigned a PI-RADS v2 score of 4.

Entities:  

Keywords:  ADC values; PI-RADS; Prostate MRI; Prostate cancer

Year:  2018        PMID: 29550953     DOI: 10.1007/s00261-018-1557-5

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  4 in total

1.  Detection of clinically signifi cant prostate cancer with PIRADS v2 scores, PSA density, and ADC values in regions with and without mpMRI visible lesions.

Authors:  Antonio C Westphalen; Farhad Fazel; Hao Nguyen; Miguel Cabarrus; Katryana Hanley-Knutson; Katsuto Shinohara; Peter R Carroll
Journal:  Int Braz J Urol       Date:  2019 Jul-Aug       Impact factor: 1.541

2.  The value of the apparent diffusion coefficient value in the Liver Imaging Reporting and Data System (LI-RADS) version 2018.

Authors:  Gehad Ahmad Saleh; Ahmed Abdel Khalek Abdel Razek; Lamiaa Galal El-Serougy; Walaa Shabana; Rihame Abd El-Wahab
Journal:  Pol J Radiol       Date:  2022-01-17

3.  Diagnostic Performance of PI-RADS v2, Proposed Adjusted PI-RADS v2 and Biparametric Magnetic Resonance Imaging for Prostate Cancer Detection: A Preliminary Study.

Authors:  Guan-Hui Cai; Qi-Hua Yang; Wen-Bo Chen; Qing-Yu Liu; Yu-Rong Zeng; Yu-Jing Zeng
Journal:  Curr Oncol       Date:  2021-05-12       Impact factor: 3.677

4.  Prostate cancer tumour control probability modelling for external beam radiotherapy based on multi-parametric MRI-GTV definition.

Authors:  Ilias Sachpazidis; Panayiotis Mavroidis; Constantinos Zamboglou; Christina Marie Klein; Anca-Ligia Grosu; Dimos Baltas
Journal:  Radiat Oncol       Date:  2020-10-20       Impact factor: 3.481

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.